Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

AUGUST 24, 2017

Educational seminar in Boston highlights significance of bone metastases

Pharmatest Services LLC arranges an educational seminar titled “Significance of Bone Metastases and Targeting Tumor, Bone and Immune System” in hotel Boston Marriott Copley Place in Boston, MA, on September 6 at 8.00 – 10.30 am.

A very large amount of oncology drugs still fail in clinical trials due to poor efficacy. One important reason for this is that compound efficacy is not confirmed in clinically relevant preclinical metastasis models before entering clinical trials. This would be important because the metastatic microenvironment changes tumor properties and induces drug resistance.

This educational seminar highlights significance of bone metastases in clinical and preclinical aspects. Keynote speaker of the seminar will be Dr. Matthew Smith from Massachusetts General Hospital Cancer Center, and other speakers will be from MassBio, Taconic Biosciences and Pharmatest.

Jussi Halleen, CEO of Pharmatest comments: “It is our mission to decrease the currently very high failure rates of oncology drugs in clinical trials, and we want to emphasize the importance of confirming compound efficacy in preclinical metastasis models to achieve this goal”.

Pharmatest welcomes everyone to join this educational seminar. You can find the seminar program and register from this link.

Pharmatest offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology Pharmatest has been the leading provider of bone metastasis models since 2005.